Maryland: The FDA has approved the emergency use of a new drug containing antibodies to protect vulnerable people from the corona virus (EUA).
The injectable drug is developed by Estraznica, dubbed Evusheld.
The FDA has clear guidelines that it can only be used by people 12 years of age or older who have a weakened immune system.
These include donated organ transplant recipients, cancer patients and those who are taking drugs that weaken the immune system. Because of all these conditions, the Covid 19 vaccine does not affect them.
This 'antibody drug' for coronavirus will be of particular benefit to all such individuals.
EvoShield consists of two antibodies that are given with two injections in the same day, after which it protects the person concerned from the corona virus for six months.
The FDA also states in its guidelines that antibody medication is only for a small percentage of people with weakened immune systems.
Therefore, people whose immune systems are normally strong do not need this antibody drug but will need to be vaccinated with the Covid 19 vaccine.
AstraZeneca trials have shown that the use of EvoShield reduces the risk of Covid 19 by 77%.
An estimated 6.6 million to 10 million people in the United States have a weakened immune system, making up 2 to 3 percent of the total population.
The US government has also immediately approved the purchase of 700,000 doses of EvoShield, but this can only be applied to a person on the advice of a doctor.
